©2024 Stanford Medicine
Outcomes of Diabetic Macula Edema Patients Switched to Aflibercept From Bevacizumab and/or Ranibizumab
Not Recruiting
Trial ID: NCT02000102
Purpose
Patients with diabetic macular edema who were switched to aflibercept after having been
treated with bevacizumab or ranibizumab were retrospectively reviewed to assess for visual
acuity and anatomic outcomes.
Stanford Investigator(s)
Theodore Leng, MD, FACS
Associate Professor of Ophthalmology and, by courtesy, of Anesthesiology, Perioperative and Pain Medicine (Adult MSD)
Eligibility
Inclusion Criteria: Those patients with diabetic macular edema switched to aflibercept from
bevacizumab and/or ranibizumab -
Exclusion Criteria: None
-
Intervention(s):
drug: Intravitreal Injection of Aflibercept
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Theodore Leng, MD
650-723-6995